After a huge drop in recent weeks, these shares look oversold -- and an insider seems to agree.
We have three new price targets.
This rally could surprise on the upside.
I'm not saying get married to the stock, I'm saying that the idea could be a trade based on two possible catalysts.
Most of the stocks in the 2022 Tax Loss Selling Recovery Portfolio are in positive territory nearly a month since inception.
We have a new price target for now.
The shares have been cut in half over the last six months.
A successful launch of ELYXYB, solid revenue growth and increasing cash flow seems on the horizon.
Blue chip stock Bristol-Myers Squibb has a high dividend yield and an excellent pipeline.
But broadening patterns can be tricky to trade.